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The metabolic syndrome (MetS) is highly prevalent and confers an increased risk of diabetes and cardiovascular disease. A
key early event in atherosclerosis is endothelial dysfunction. Numerous groups have reported endothelial dysfunction in MetS.
However, the measurement of endothelial function is far from optimum. There has been much interest recently in a subtype of
progenitorcells,termedendothelialprogenitorcells(EPCs),thatcancirculate,proliferate,anddﬀerentiateintomatureendothelial
cells. EPCs can be characterized by the assessment of surface markers, CD34 and vascular endothelial growth factor receptor-
2, VEGFR-2 (KDR). The CD34+KDR+ phenotype has been demonstrated to be an independent predictor of cardiovascular
outcomes. MetS patients without diabetes or cardiovascular diseases have decreased EPC number and functionality as evidenced
by decreased numbers of colony forming units, decreased adhesion and migration, and decreased tubule formation. Strategies
that have been shown to upregulate and enhance EPC number and functionality include statins, angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, and peroxisome-proliferator-activating-receptor gamma agonists. Mechanisms bywhich
they aﬀect EPC number and functionality need to be studied. Thus, EPC number and/or functionality could emerge as novel
cellular biomarkers of endothelial dysfunction and cardiovascular disease risk in MetS.
1.Introduction:TheMetabolicSyndrome
The metabolic syndrome (MetS) comprises a cluster of ab-
normalities, with insulin resistance (IR) and adiposity as
central features [1]. Five diagnostic criteria have been identi-
ﬁed by the National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III), and the presence
of any three features (central obesity, dyslipidemia [high
triglycerides, low HDL], hypertension, and impaired fasting
glucose) is considered suﬃcient to diagnose the syndrome.
Approximately 35% of US adults have the MetS and this
appears to be a very common syndrome globally. Also, the
prevalence increases with age [2]. MetS confers a two- to
fourfold increased risk for cardiovascular disease (CVD) and
ﬁvefold increased risk of diabetes [3].
2.Endothelial DysfunctionandMetS
A key early event in atherosclerosis is endothelial cell dys-
function, which is precipitated by several noxious insults
including obesity, hypertension, and dyslipidemia hyper-
glycemia, all features of MetS. Numerous groups have
reported endothelial dysfunction in patients with MetS.
Espositoetal.showedthatcomparedwith60controlsubjects
matched for age and sex, patients with the metabolic syn-
drome had decreased endothelial function [4]. In the Fram-
ingham Oﬀspring participants, Hamburg et al. [5] showed,
in age and gender adjusted models, that MetS was associated
with decreased ﬂow-mediated dilation (FMD). There was
progressively lower vasodilator function with increasing
numberofMetScomponents.Lteifetal.,usinglegbloodﬂow2 Experimental Diabetes Research
measurements, showed that patients with MetS had worse
endothelial function [6]. Also, in the Prospective Study of
the Vasculature in Uppsala Seniors (PIVUS) study, using dif-
ferent techniques to assess vasodilation in conduit and resis-
tance arteries in MetS, the authors showed decreased ﬂow-
mediated vasodilation (FMD) [7]. In the Northern Manhat-
ten study (NOMA), Suzuki et al. reported that MetS was
associated with decreased ﬂow-mediated dilatation (FMD)
and increased CVD over 81 months [8]. Thus, it is clear that
MetS patients have impaired endothelial function. This has
major implications with regards to subsequent CVD.
However, despite being used in several studies, the mea-
surement of endothelial function by ﬂow-mediated dilation
is far from optimum and there is much variability in the
studies reported above such as the NOMA and Framingham
studies in which the mean FMD in controls were 6.3 and
3.3%, respectively.
3.Endothelial ProgenitorCells(EPC)
There has been much interest recently in a sub-type of pro-
genitor cells, isolated from bone marrow, umbilical vessels,
and peripheral blood of adults that have the capacity to
circulate, proliferate, and diﬀerentiate into mature endothe-
lial cells, termed endothelial progenitor cells (EPCs). EPCs
circulate in the blood and appear to home preferentially to
sites of vascular or tissue injury, contributing signiﬁcantly
to both reendothelialization and neoangiogenesis. It needs
to be stated at the outset that there is much controversy
with respect to the correct deﬁnition of EPCs [9–11].
Generally, it is accepted that EPCs are characterized by the
assessment of surface markers such as CD34 and vascular
endothelial growth factor receptor-2, VEGFR-2 (KDR) [11].
Importantly, CD34+KDR+ combination is the only putative
EPC phenotype that has been demonstrated repeatedly and
convincingly to be an independent predictor of cardiovascu-
lar outcomes [12, 13].
4.EPCandCardiovascularEvents
In a 10-month follow-up study, Schmidt-Lucke et al.
[14] showed that the level of CD34+KDR+ cells indepen-
dently predicted cardiovascular events and progression of
atherosclerosis in a mixed population of healthy subjects
and cardiovascular patients. In a larger study, Werner et al.
[15] have reported that CD34+KDR+ cell count predicted
cardiovascular events and cardiovascular death during a 12-
month followup in 519 patients with coronary artery disease
(CAD). Also, in a subset, colony forming units (CFUs)
predicted cardiovascular events. Furthermore, Hill et al.
[16] reported a strong correlation between the number of
circulating endothelial progenitor cells (measured as colony
forming units (CFUs)) and the subjects’ combined Fram-
ingham risk factor score. Also, the measurement of ﬂow-
mediated brachial-artery reactivity revealed a signiﬁcant
relation between endothelial function and the number of
progenitor cells. Indeed, levels of circulating EPC were a
better predictor of vascular reactivity than was the presence
or absence of conventional risk factors. Fadini et al. showed
thatalowCD34count,ameasureofprogenitorcells,inaddi-
tion to metabolic syndrome was associated with increased
cardiovascular events (CVEs) [17]. Fadini’s group have also
shown an association between EPC reduction and increased
carotid intima media thickness (c-IMT), as a marker of early
atherosclerotic remodeling in healthy subjects [18].
In addition to ﬂow cytometric quantitation of CD34/
KDRpredicting CVE, alsofunctionalassayssuchasCFUand
EPC migration have been shown to correlate signiﬁcantly
withCADriskfactors,severity,andevents[12–16].Thus,the
measurementofEPCsmaybeasurrogatebiologicmarkerfor
vascular function and cumulative cardiovascular risk, sug-
gesting further that endothelial injury in the absence of
suﬃcient circulating progenitor cells may unfavorably aﬀect
the progression of CVD.
Additionally, various risk factors for CVD have been
shown to impair EPCs in terms of functional features: prolif-
eration (important for amplifying the cellular pool), migra-
tion (critical for homing of circulating EPCs), and survival
[19]. Furthermore, decrease in circulating EPCs contributes
toimpairedangiogenesis aswellasprogressionofatheroscle-
rosis and patients at risk for CAD have decreased number
of circulating EPCs with impaired activity. Thus, it seems
important that both the number and functional activity of
EPCs should be investigated. The individual components of




and functionality [21]. There appears to be two studies
that have directly looked at EPC number in MetS patients
(without other confounding, comorbidities such as diabetes
orcardiovasculardisease)andmatchedcontrols.Inthestudy
by Westerweel et al., they show that circulating CD34+KDR+
EPC levels were reduced by nearly 40% in obese men with
MetS compared to nonobese men [22]. Although this was
a small study that included 19 patients with MetS, it is
important to emphasize that in this study, they excluded
patients with overt clinical CVD or diabetes. They did not
study EPC functionality.
In the study by Jialal et al. [23] ,t h e yr e p o r t e do nE P C
number and functionality in a larger sample size of subjects
with MetS (n = 46) of which 77% were female and matched
controls (n = 31). In accord with the study in obese males,
they showed a signiﬁcant decrease in EPC number, also
deﬁned by CD34/KDR dual positivity. Furthermore, these
investigators also looked at functionality of EPCs such as
colony forming units, migration, and tubule formation [23].
In addition to the reduction in numbers, they showed that
there were signiﬁcant impaired clonogenic capacity and also
an impaired capacity to incorporate into tubule structures.
Whilst there was a decrease in migration of the EPCs in
MetS this did not attain signiﬁcance. However, it needs to
be emphasized that none of the subjects were diabetic or had
CVD in the above 2 studies and none were on medicationsExperimental Diabetes Research 3
that aﬀect EPCs suggesting that the defect in EPCs manifest
early in nascent MetS prior to the development of diabetes
or CVD. Fadini et al. have reported in a study decreased
circulating EPCs and progenitor cells in diabetic patients
with peripheral vascular disease [24]. In this paper, they
did a subgroup analysis of MetS patients versus non-MetS
patients. However, not much detail is provided with respect
to coexistent diseases and morbidity such as diabetes and
peripheral vascular disease or concomitant medications in
these two subgroups. Since, this was a study with the
primary aim to look at EPC status in diabetic patients with
peripheral vascular disease the data in patients in MetS is
not as detailed as reported in the 2 studies that focused
on MetS alone [22, 23]. In a subsequent report by Fadini
et al., they showed that in patients with MetS, there was a
decrease in progenitor cells (CD34+ cells) [17]. It appears
that many of these patients also could have diabetes, and
be on medications such as statins, angiotensin converting
enzyme Inhibitors (ACE-I), angiotensin receptor blockers
(ARBs), and antidiabetic therapy such as pioglitazone, which
couldhaveinﬂuencedthedata[24].Ther eport eddecr easein
progenitor cells in these 2 studies was conﬁrmed in the study
by Jialal et al. [23]. Previously, Satoh et al. [25]h a v er e p o rt e d
increased EPC number in CAD patients with MetS and
withoutMetS.TheydidnotcomparepatientswithMetSwith
controls and their sample sizes were small (n = 15 for acute
myocardial infarction and n = 16 for patients with stable
angina angina pectoris and MetS, resp.). Interestingly, they
also showed increased oxidative DNA damage, decreased
telomerase activity, and decreased telomere length, a marker
of increased senescence in EPCs of CAD patients with MetS
than the CAD patients without MetS. This suggests that the
increase in EPC with CVD was a dysfunctional population
since EPCs are generally well endowed with antioxidant
defenses. Other functional measures of EPC activity such
as tubule formation or colony forming units or adhesion
was not investigated in this study. Thus, this needs to be
investigated further.
Recently, Vignera et al. [26] reported increased EPCs
in patients with arterial erectile dysfunction and MetS
compared to controls. It is possible that in ED, where there
is profound vascular dysfunction, a particular subtype of
EPC (CD45 negative, CD34 positive, and CD144 positive)
are increased due to a compensatory increase in mobilizing
factors and could depict repair mechanisms. It is however
important to point out that these investigators did not
use the classical CD34/KDR criteria. Furthermore, the
increased EPC in their subjects correlated with endothelial
microparticles (EMPs) and IMT suggesting that this is a
dysfunctional population. However since they did not study
EPC functionality unlike the study by Satoh et al. [25], one
cannot critically appraise this report. Also, limited data is
provided with respect to medications that can aﬀect EPC
numbers and comorbidities such as diabetes and CVD,
which are common accompaniments of erectile dysfunction
and could further inﬂuence their ﬁndings. Indeed, previous
studies have also reported decreased EPCs in such patients
and a signiﬁcant correlation of the decreased EPCs to
increased cardiovascular risk.
There is very limited data that speciﬁcally looked at EPC
status either number and/or functionality in patients with
MetS without the complications of diabetes and CVD. In
the two studies which speciﬁcally address this, both have
shown, decreased number of EPC, they are at variance
with respect to a decrease in progenitor cells since levels
were not signiﬁcantly lower in the study in obese males.
HoweverifthedatafromthestudiesbyFadiniareconsidered
one could conclude that progenitor cell exhaustion can be
advanced as one mechanism resulting in decrease in EPC
number [27]. In addition, in the Jialal et al. [23] study, they
showed signiﬁcant correlation of CRP levels in MetS with
decreased EPC number and functionality, pointing to the
role of inﬂammation in this process.
There is limited data with regards to mobilizing factors
in patients with MetS. Egan et al. [28] have reported the
profound reduction in EPCs due to impaired mobilization
from bone marrow because of the lower expression of CXC
Chemokine Receptor 4 (CXCR4+)/CD34+ cells in diabetics
versus controls. Importantly, CXCR4, CD117, and KDR are
deﬁned as the mobilizing receptors for progenitor cells (PCs)
[29, 30]. Thus, it appears that the measurement of the
respective circulating ligands; vascular endothelial growth
factor (VEGF) for KDR, soluble c-kit ligand (KitL) for
CD117, and Stromal derived factor 1 (SDF-1) for CXCR4
is also important. Some of the accepted mobilizing factors
include VEGF, stromal derived factor-1 (SDF-1), and c-kit
ligand [30]. In a small study that has examined mobilizing
factors in MetS, the investigators showed no signiﬁcant
diﬀerences in VEGF levels, but showed that progenitor
cell mobilizing stromal cell-mobilizing factor (SCF) and
the soluble form of SCF receptor c-kit were both reduced
in patients with MetS [22]. Since this is a limited study
in a small number of patients, these ﬁndings need to be
conﬁrmed in a larger study. Jialal et al. [31] recently showed
insubjectswithMetS(n = 36)comparedtoage-andgender-
matched controls (n = 38) that there was a signiﬁcant
reduction of 83% in granulocyte colony-stimulating factor
levels in patients with MetS. Also, there were decreases in
SCF and SCF soluble receptor levels. However, there was no
signiﬁcant diﬀerence in stromal cell-derived factor-1 levels,
and paradoxically, vascular endothelial growth factor levels
were increased, consistent with VEGF resistance, which has
been reported previously with insulin resistant states such as
diabetes and MetS [32]. Data on matrix metalloproteinase
(MMP)-9 levels in patients in MetS is sparse. Previously,
MMP-9 levels have been shown to be increased in subjects
with MetS using immunoassay [33]. Since MMP-9 levels are
criticalforhomingofEPC[34],weexaminedlevelsofMMP-
9. In accord with the previous report we show an increase
in MMP 9 levels by immunoassay (Figure 1). However the
relevance of this ﬁnding is questionable since we did not
assay enzyme activity by zymography which is the superior
measure of MMP-9 activity.
Thus, whilst there is much controversy with regards to
the nomenclature and deﬁnition of EPCs, it needs to be
emphasized that EPC number, EPC migration, and colony
forming units which appear to connote early EPCs have
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Figure 1: MMP-9 Levels in Patients with MetS compared to
matched controls. Plasma MMP-9 levels were measured in patients
with MetS compared to matched healthy controls (n = 38 and
36/group, resp.) using a sandwich ELISA (R&D Biosystems). Data
are expressed as mean ± S.D in ng/mL. ∗∗P<0.01 compared to
controls.
severity and predict CVD events to date. However, whilst
it is claimed that the late EPCs are more likely to become
endothelial cells, it needs to be emphasized that to date no
studies have reported that late EPCs predict CVE in patients
[30].
Thus, the published studies have shown that EPC
numbers and functionality is impaired in MetS. The poten-
tial mechanisms that have been advanced so far include
decreased progenitor cells and dysregulation of EPC mobi-
lizing factors. Longevity of EPC in MetS has not been
reported and thus studies directed at telomere biology and
apoptosis are urgently needed in patients with MetS without
comorbidities.
Inconclusion,EPCnumberandfunctionalitycouldserve
as an additional novel cellular biomarker of endothelial
integrity and impaired neoangiogenesis in patients with
MetS who clearly have manifest endothelial dysfunction.
Prospective studies should demonstrate that they predict
CVD. Strategies that have been shown to upregulate and
enhance EPC number and functionality such as statins,
ACE-I, ARBs, PPAR-gamma agonist, and INCRETIN-based
therapies, need to be studied more carefully with respect
to both number and functionality of EPCs since this
could inform us of their direct beneﬁcial eﬀects on the
vulnerable vasculature of Mets. Thus, EPC number and/or
functionality could emerge as a novel cellular biomarker of
CVD risk and could better inform clinicians about potential
pharmacotherapy for patients with MetS.
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